Lava Therapeutics Company

Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of cancer.

Last Funding Date: 2020-09-17
Investors Number: 9
Industry: Atrificial Vectors and Immune Cells
Last Funding Type: Series C
Headquarters: Utrecht, Utrecht, The Netherlands
Total Funding: 102854807
Funding Status: IPO
Employee Number: 51-100
Estimated Revenue: $1M to $10M
Founded Date: 2016-01-01